

EQA round: RFA1/23 - Risk Factors for Atherosclerosis

Deadline: 7.4.2023

Setup: groups - measurement principle; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(114) Apolipoprotein AI	[g/L]				13							13	12	92
Sample A												13	12	92
(2) Immunoturbidimetry		1,06	0,088	8,4	13	0	CVP	1,07	0,019	21%	0,845	1,3	13	
Sample B												13	13	100
(2) Immunoturbidimetry		2,26	0,18	7,8	13	0	CVP	2,31	0,043	21%	1,82	2,8	13	
(115) Apolipoprotein B	[g/L]				15							15	14	93
Sample A												15	14	93
(2) Immunoturbidimetry		0,557	0,048	8,6	15	0	CVP	0,552	0,008	18%	0,452	0,652	15	
Sample B												15	15	100
(2) Immunoturbidimetry		1,26	0,066	5,2	15	0	CVP	1,27	0,012	18%	1,04	1,5	15	
(111) Cholesterol	[mmol/L]				40							40	39	98
Sample A												40	40	100
(0) Not specified		3,08	0,098	3,2	40	0	CVP	3,06	0,013	8%	2,81	3,31	40	
Sample B												40	39	98
(0) Not specified		7,09	0,22	3,2	40	0	CVP	6,99	0,029	8%	6,43	7,55	40	
(113) Cholesterol HDL	[mmol/L]				40							40	40	100
Sample A		0,974	0,046	4,7	40		CVP	0,986	0,006	15%	0,838	1,14	40	40
(2) Direct determination		0,976	0,044	4,5	39	0						39		
Other					1	0						1		
							1x 1							
Sample B		2,07	0,069	3,3	40		CVP	2,07	0,012	15%	1,75	2,39	40	40
(2) Direct determination		2,07	0,071	3,4	39	0						39		
Other					1	0						1		
							1x 1							
(118) Cholesterol LDL (direct determination)	[mmol/L]				33							33	33	100
Sample A												33	33	100
(0) Not specified		1,79	0,13	7,1	33	0	CVP	1,78	0,02	20%	1,42	2,14	33	
Sample B												33	33	100
(0) Not specified		4,19	0,38	9,1	33	0	CVP	4,16	0,06	20%	3,32	5	33	
(116) Cholesterol LDL (calculation)	[mmol/L]				10							10	10	100
Sample A												10	10	100
(0) Not specified		1,67	0,13	8,1	10	0	CVP	1,66	0,023	15%	1,41	1,91	10	
Sample B												10	10	100
(0) Not specified		4,01	0,25	6,3	10	0	CVP	3,98	0,05	15%	3,38	4,58	10	
(117) Lipoprotein (a) [g/L]	[g/L]				7							7	5	71
Sample A		0,074	0,028	38	7		CVP	0,086	0,006	36%	0,055	0,117	7	6
(2) Immunoturbidimetry		0,074	0,028	38	6	0						6		
Other					1	0						1		
							1x 3							
Sample B		0,259	0,062	24	7		CVP	0,276	0,011	25%	0,207	0,345	7	6
(2) Immunoturbidimetry		0,268	0,047	18	6	0						6		
Other					1	0						1		
							1x 3							
(119) Lipoprotein (a) [nmol/L]	[nmol/L]				4							4	4	100
Sample A												4	4	100
Other					4	0						4		
							4x 2							
Sample B												4	4	100
Other					4	0						4		
							4x 2							
(112) Triacylglycerols	[mmol/L]				40							40	40	100
Sample A		0,906	0,038	4,2	40		CVP	0,911	0,006	15%	0,774	1,05	40	40
(1) Photometric enzyme (GPO-PAP)		0,906	0,037	4,1	37	0						37		
Other					3	0						3		
							3x 2							
Sample B		2,08	0,058	2,8	40		CVP	2,09	0,009	15%	1,77	2,41	40	40
(1) Photometric enzyme (GPO-PAP)		2,08	0,059	2,8	37	0						37		
Other					3	0						3		
							3x 2							